AMGEN Inc. (AMGN) Company Profile & Statistics

AMGEN Inc.
AMGN
(Nasdaq - US)
Closed
289.88
+2.01 (+0.70%)
in:usd•As of: Nov 21, 2024 15:59 UTC -5
After Market:290.01+0.13 (+0.04%)
Open
286.43
High
291.05
Low
284.18

About AMGEN Inc.

CEO

Robert A. Bradway

Headquarters

one amgen center drive

thousand oaks, ca 91320, united states

Auditor

Ernst & Young LLP

Employees

26,700

Share Holders

4,614

Website

www.amgen.com

Industry

biotechnology

Sector

health technology

Company Overview

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.

AMGEN Inc. Statistics

Valuation Measures

Market Capitalization ²	155.82B
Enterprise Value	207.21B
Enterprise Value/EBITDA (ttm)	17.57
Price to Earnings Ratio (ttm)	14.57
Price to Book (mrq)	19.99
Price to Sales (ttm)	4.63
Price to Cash (ytd)	10.62

Profitability

Gross Margin (ttm)	60.39%
Operating Margin (ttm)	31.96%
Profit Margin (ttm)	12.50%
Return on Equity (ttm)	168.35%
Return on Invested Capital (ttm)	6.51%
Return on Assets (ttm)	11.18%

Income Statement

Revenue (ttm)	32.53B
Revenue Per Share (ttm)	60.52
Gross Profit (ttm)	19.68B
EBITDA (ttm)³	11.79B
Net Income Avi to Common (ttm)	4.23B
Diluted EPS (ttm)	7.81

Share Statistics

Beta (5Y Monthly)	0.60
52-Week Change	11.65%
S&P500 52-Week Change	31.08%
S&P500 Member	Yes
Stock Optionable	Yes
Total Shares Outstanding ¹	537.53M
Dividend Yield	3.21%
Float ⁴	533.82M
% Held by Insiders	0.69%
% Held by Institutions	76.50%

Balance Sheet

Total Cash (mrq)	9.01B
Total Cash Per Share (mrq)	16.76
Total Debt (mrq)	60.40B
Total Debt/Equity (mrq)	802.42%
Current Ratio (mrq)	1.32%
Quick Ratio (mrq)	0.96%
Book Value Per Share (mrq)	14.00

Cash Flow

Operating Cash Flow Per Share (ytd)	12.40
Free Cash Flow (ytd)	5.99B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

AMGEN Inc.

Trade With A Regulated Broker